HOOKIPA will reduce its workforce by approximately 30% and rebalance its cost structure in alignment with the new prioritization of the Company’s programs. HOOKIPA maintains a strong cash position of $117.5 million as of December 31, 2023, and believes that the planned reductions will help to conserve resources and better align its organization in direct support of late-stage clinical development efforts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HOOK:
- HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
- Hookipa Pharma appoints WInderlich as Chief Development Officer
- HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
- Hookipa Pharma files to sell 15M shares of common stock for holders
- HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
